| 林敏佳,叶泽笑,汝触会,牛天水,何飞.痰热清胶囊治疗支气管扩张症型非结核分枝杆菌肺病痰热壅肺证疗效观察[J].浙江中西医结合杂志,2026,36(4): |
| 痰热清胶囊治疗支气管扩张症型非结核分枝杆菌肺病痰热壅肺证疗效观察 |
|
| 投稿时间：2025-04-30 修订日期：2026-02-17 |
| DOI： |
| 中文关键词: 痰热清胶囊，支气管扩张症，非结核分枝杆菌肺病，临床研究 |
| 英文关键词: |
| 基金项目:1.杭州市科技计划项目(2022WJC110)；2. 浙江省中医药科学研究基金项(No.2025ZL450)；3.浙江省老年心肺疾病中医药创新团队项目(浙卫发[2023]31号);4.国家中医优势专科感染科建设项目(国中医药医政函[2024]90号)。 |
|
| 摘要点击次数: 8 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:观察痰热清胶囊联合西药治疗支气管扩张症型非结核分枝杆菌肺病痰热壅肺证疗效。方法:将62例支气管扩张症型非结核分枝杆菌肺病痰热壅肺证患者随机分组，每组各31例。对照组根据指南给予基础临床治疗，观察组在对照组治疗上给予痰热清胶囊治疗，各组疗程为10天。在研究开始及结束时分别对各组进行中医证候积分、肺CT形态和炎症指标等各项检测。结果:各组治疗后中医证候积分均较治疗前有显著性差异（P＜0.05），治疗后观察组较对照组中医证候积分显著减少（P＜0.05）；观察组肺部CT病灶稳定及改善比例与对照组比较，差异无统计学意义（P>0.05）；对照组CRP治疗前后比较，差异有统计学意义（P<0.05），观察组WBC、NLR、LYM及CRP治疗后均较治疗前显著改善（P均<0.05）；治疗后与对照组比较，观察组NLR显著下降，LYM显著升高，差异均有统计学意义（P<0.05）。结论:痰热清胶囊联合常规西医基础对痰热壅肺型支气管扩张症型非结核分枝杆菌肺病治疗效果优于单独使用西医治疗，可能与其更好改善患者临床症候、炎症情况及促进免疫重建有关。 |
| 英文摘要: |
| Objective: To observe the curative effect of Tanreqing capsule combined with western medicine in the treatment of bronchiectasis with non-tuberculous mycobacterial lung disease with TanRe YongFei syndrome. Methods: 62 patients with bronchiectasis with non-tuberculous mycobacterial lung disease with TanRe YongFei syndrome were randomly divided into two groups, 31 cases in each group. The control group was given basic clinical treatment according to the guidelines, and the observation group was given Tanreqing Capsule on the basis of basic treatment. The course of treatment in each group was 10 days. At the beginning and end of the study, each group was tested for TCM syndrome scores, lung CT morphology and inflammatory indicators.. Results: After treatment, the scores of TCM syndromes in each group were significantly different from those before treatment ( P < 0.05 ) . After treatment, the scores of TCM syndromes in the observation group were significantly lower than those in the control group ( P < 0.05 ); The proportion of stable and improved lung lesions on CT in the observation group was not statistically different from the control group (P>0.05); The control group showed a statistically significant difference in CRP before and after treatment (P<0.05), and the observation group showed significant improvement in WBC, NLR, LYM and CRP after treatment compared with before treatment (all P<0.05); After treatment, the observation group showed a significant decrease in NLR and a significant increase in LYM compared with the control group, with statistical significance (P<0.05). Conclusion: Tanreqing capsules combined with conventional western medicine are more effective than western medicine alone in the treatment of bronchiectasis-type non-tuberculous mycobacterial pneumonia with TanRe YongFei syndrome, which may be related to improving clinical symptoms, inflammation and promoting immune reconstitution. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
